Boston Scientific Corporation (BSX) is in the news for multiple reasons. The firm's securities fraud lawsuit continues with shareholders who lost money given the opportunity to lead. Truist has cut its price target from $95 to $92 on the company's stock, explaining a market pullback despite impressive financial results. Multiple investment firms, including Danske Bank and Stance Capital, have increased their holdings in BSX, while others like Jain Global have decreased theirs. Amidst these developments, Boston Scientific announces a $5 billion share buyback authorization. Its stock has outpaced the general market, attracting attention from investors like Needham & Company, who've reaffirmed a buy rating on the stock. At the same time, BSX stockholders face a securities class action deadline on May 4, 2026. Key players, Union Bancaire Privee UBP SA, and National Bank of Canada FI have purchased shares while there is a significant decrease in holdings by Holocene Advisors LP. Furthermore, the price target got lowered by Stifel Nicolaus to $90.00 and UBS Group to $105. In the face of these developments, Boston Scientific announces plans to acquire Penumbra, Inc, releasing its Q4 earnings and electing new members of its Board of Directors.
Boston Scientific Corp BSX News Analytics from Tue, 14 Oct 2025 07:00:00 GMT to Sat, 21 Mar 2026 10:29:11 GMT -
Rating 0
- Innovation 4
- Information 6
- Rumor -3
